An observational study in Hidradenitis Suppurativa, sponsored by Novartis Pharmaceuticals. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Hidradenitis Suppurativa by Novartis — 9 open to participants now, 14 under way, 3 of them phase 3. Hidradenitis Suppurativa · Novartis.
Among the 21 studies in Hidradenitis Suppurativa by Novartis, this one is the 4th largest by planned enrollment of the 10 observational ones that give a count, is one of 5 that started in 2026, is one of 10 observational ones, reaches primary completion later than 2 of the 13 other live ones, and was the 20th registered.
286 studies on the registry are indexed under Hidradenitis Suppurativa; 89 are open to participants now.
Browse Hidradenitis Suppurativa studies →9 of the 21 studies in Hidradenitis Suppurativa by Novartis are open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States
Ages 18–65
Novartis Pharmaceuticals · Sites in United States, Argentina, Australia and 9 more countries
Ages 18–100
Novartis Pharmaceuticals · Sites in China
Ages 18+
Novartis Pharmaceuticals · Sites in Korea, Republic of
Ages 6–100
Novartis Pharmaceuticals · Sites in Italy
Ages 18–100
By country, each count listing its studies:
Of the 63 Hidradenitis Suppurativa studies recruiting now, 35 (56%) set no upper age limit and 17 (27%) stop at 75 or younger; 13 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 186 is close to the median of 175 across 73 observational studies indexed under Hidradenitis Suppurativa.
Median enrollment 545 across the 10 interventional studies, 125 across the 10 observational. Of the 6 that completed or were terminated, 5 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,723 studies on the registry; 222 are open to participants now.
Of its 587 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
9 of the studies in Hidradenitis Suppurativa by Novartis that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06799000Phase 3Novartis PharmaceuticalsA Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1) | 2027-05-17 |
| NCT06840392Phase 3Novartis PharmaceuticalsA Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa | 2027-06-03 |
| NCT06517732Novartis PharmaceuticalsStudy to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (HS) in Routine Clinical Practice in the Russian Federation | 2026-12-31 |
| NCT07690319Novartis PharmaceuticalsA Study of Early Secukinumab Treatment in Moderate to Severe Hidradenitis Suppurativa Patients | 2027-03-15 |
| NCT05921994Novartis PharmaceuticalsLong Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of secukinumAb in Adult Patients With Moderate to Severe Hidradenitis Suppurativa. | 2027-03-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 21 studies in Hidradenitis Suppurativa by Novartis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this study is to evaluate the effectiveness of early treatment with secukinumab in patients with moderate-to-severe hidradenitis suppurativa (HS) and assess its impact on disease progression using data from multiple European data sources. All data will be sourced from existing non-interventional study primary data collection, registries, and hospital cohorts that captured information collected in routine clinical practice, prior to and independent of this study.
Adult patients with moderate-to-severe HS who initiated secukinumab treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Other protocol-defined inclusion/exclusion criteria may apply.
Adult patients with moderate to severe HS, having up to 1 active tunnel (draining or non-draining) or up to 4 inflammatory lesions (abscess/nodules) at date of first secukinumab administration for HS treatment.
Adult patients with moderate to severe HS, having \>1 active tunnel or \>4 inflammatory lesions, at date of first secukinumab administration for HS treatment.
Proportion of Patients Achieving 55% Reduction From Baseline in International Hidradenitis Suppurativa Severity Scoring System (IHS4-55) at 6 and 12 Months
The International Hidradenitis Suppurativa Severity Scoring System (IHS4) is a validated measure of HS severity. Disease severity is calculated by weighting different lesion types as follows: the IHS4 score = (number of nodules × 1) + (number of abscesses × 2) + (number of draining tunnels \[fistulae/sinuses\] × 4). A score of ≤3 indicates mild disease, a score of 4-10 indicates moderate disease, and a score of ≥11 indicates severe disease. In this study, treatment response is assessed using IHS4-55, defined as a proportion of patients achieving ≥55% reduction in IHS4 score compared to baseline.
Time frame: 6 and 12 months
Number and Percentage of Patients by Selected Demographic and Clinical Characteristics Overall and by Early and Late Treatment Group
Demographics and clinical characteristics (subject to availability in the data sources) include: * Age category * Sex * Body mass index (BMI) category * Smoking status * Other medical conditions * Family history of HS * Year of HS diagnosis * Year of secukinumab initiation * Hurley stage * Number of tunnels, nodules, abscesses * Prior surgeries and procedures * Prior treatment
Time frame: Baseline
Duration of HS
Time frame: Baseline
Mean Change From Baseline in IHS4 Score at 6 and 12 Months
The IHS4 is a validated measure of HS severity. Disease severity is calculated by weighting different lesion types as follows: the IHS4 score = (number of nodules × 1) + (number of abscesses × 2) + (number of draining tunnels \[fistulae/sinuses\] × 4). A score of ≤3 indicates mild disease, a score of 4-10 indicates moderate disease, and a score of ≥11 indicates severe disease.
Time frame: Baseline, 6 and 12 months
Proportion of Patients Achieving 75% Reduction in IHS4 (IHS4-75) From Baseline at 6 and 12 Months
The IHS4 is a validated measure of HS severity. Disease severity is calculated by weighting different lesion types as follows: the IHS4 score = (number of nodules × 1) + (number of abscesses × 2) + (number of draining tunnels \[fistulae/sinuses\] × 4). A score of ≤3 indicates mild disease, a score of 4-10 indicates moderate disease, and a score of ≥11 indicates severe disease. IHS4-75 is defined as a proportion of patients achieving ≥ 75% reduction in IHS4 score at 6 and 12 months compared to baseline.
Time frame: 6 and 12 months
Proportion of Patients Achieving 100% Reduction in IHS4 (IHS4-100) From Baseline at 6 and 12 Months
The IHS4 is a validated measure of HS severity. Disease severity is calculated by weighting different lesion types as follows: the IHS4 score = (number of nodules × 1) + (number of abscesses × 2) + (number of draining tunnels \[fistulae/sinuses\] × 4). A score of ≤3 indicates mild disease, a score of 4-10 indicates moderate disease, and a score of ≥11 indicates severe disease. IHS4-100 is defined as a proportion of patients achieving 100% reduction in IHS4 score at 6 and 12 months compared to baseline.
Time frame: 6 and 12 months
Mean Change in Number of Inflammatory Abscesses, Nodules, and Active Tunnels From Baseline at 6 and 12 Months
Time frame: Baseline, 6 and 12 months
Proportion of Patients Whose Disease Progresses From Baseline at 6 and 12 Months
Disease progression is defined as development of new tunnel(s) or development of new persistent HS lesions in an anatomical area not previously affected or increase in the number of persistent HS lesions in an affected anatomical region. Persistent lesions are defined as lesions sustained for ≥4 weeks.
Time frame: 6 and 12 months
Mean Number of Flares From Baseline at 6 and 12 Months
Flare is defined as an increase of at least 25% in AN (abscess and inflammatory nodule) count with a minimum increase of 2 AN relative to baseline.
Time frame: 6 and 12 months
Mean Change in Pain From Baseline at 6 and 12 Months
Patient-reported Numeric Rating Scale (NRS) skin pain score at 6 and/or 12 months, as recorded. The Skin Pain NRS is a tool used to measure patient reported skin pain severity. Patients rate their worst skin pain over the past 24 hours on a scale from 0 (no pain) to 10 (worst pain imaginable).
Time frame: Baseline, 6 and 12 months
Proportion of Patients Achieving ≥30% Reduction in Patient's Global Assessment of Skin Pain Numeric Rating Scale (NRS30)
The Skin Pain NRS is a tool used to measure patient reported skin pain severity. Patients rate their worst skin pain over the past 24 hours on a scale from 0 (no pain) to 10 (worst pain imaginable). An NRS30 response is defined as a ≥30% reduction and ≥2-point decrease in skin pain score from baseline.
Time frame: 6 and 12 months
Proportion of Patients Who Required Surgery From Baseline at 6 and 12 Months
Any HS-related surgery (e.g., STEEP, wide excision, incision and drainage, deroofing) between baseline and at 6 and/or 12 months, as reported.
Time frame: 6 and 12 months
Proportion of Patients Achieving a 5-point Reduction of Their Dermatology Life Quality Index (DLQI) Questionnaire From Baseline at 6 and 12 Months
The DLQI is a questionnaire designed to measure the impact of skin disease on a patient's health-related quality of life. It contains 10 simple, self-administered items. Each item is scored on a 4-point scale (0 = not at all to 3 = very much). The total score ranges from 0 to 30, with higher scores indicating greater impairment in quality of life.
Time frame: 6 and 12 months
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Mar 2027, 4 months later.
Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Nov 2026, on Oct 20, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.